More articles from Lung cancer

30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Jacobus Adrianus Burgers, Ronald Alphons Damhuis

ERJ Open Research Oct 2018, 4 (4) 00030-2018; DOI: 10.1183/23120541.00030-2018
New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey
Thierry Berghmans, Matthew Evison, Torsten Gerriet Blum, Nir Peled, Jacques Cadranel

ERJ Open Research Jul 2018, 4 (3) 00040-2018; DOI: 10.1183/23120541.00040-2018
Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening?
Tanel Laisaar, Bruno Sarana, Indrek Benno, Kaja-Triin Laisaar

ERJ Open Research Jul 2018, 4 (3) 00001-2018; DOI: 10.1183/23120541.00001-2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel

ERJ Open Research Apr 2018, 4 (2) 00120-2017; DOI: 10.1183/23120541.00120-2017
Outcome of advanced lung cancer with central airway obstruction versus without central airway obstruction
Akash Verma, Soon Keng Goh, Dessmon Y.H. Tai, Ai Ching Kor, Chun Ian Soo, Debra G.F. Seow, Zin Nge Nge Sein, Jens Samol, Akhil Chopra, John Abisheganaden

ERJ Open Research Apr 2018, 4 (2) 00173-2017; DOI: 10.1183/23120541.00173-2017

Main menu

User menu

Search

More articles from Lung cancer